January 18, 2025: National Center for Health Research questioned CMS’ proposed Medicare coverage with evidence development (CED coverage) for TTVR because the device isn’t proven to save lives or reduce hospitalization. In our written public comment, we said that patients’ quality of life is also very important, but it should be evaluated in an unbiased way that does not make a device seem more beneficial than it really is.
Read More »On Medical Treatments & Products
NCHR Comment on Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Falls and Fractures in Community-Dwelling Adults
January 21, 2025: NCHR written public comment supporting the conclusions drawn by the USPSTF and providing suggestions for improvements of their draft recommendation about Calcium, Vitamin D, and combined supplementation to prevent falls and fractures.
Read More »National Center for Health Research Comment on USPSTF Draft Recommendations on Cervical Cancer Screening
January 13, 2025: Our public comment on the USPSTF draft recommendation for cervical cancer screening emphasized the need for balanced screening strategies. We highlighted the importance of integrating cytology as a triage step after HPV-positive results, addressing follow-up care, and ensuring equitable access to minimize overtreatment and psychological distress.
Read More »NCHR Public Comment Regarding Device Trial Participation Snapshots
January 13, 2025: In response to FDA’s draft of medical device Snapshots, NCHR urged FDA to add more information about risks and benefits in wording that is easy to understand. The information should also quantify the risks and benefits and explain the implications of the strengths and weaknesses of the evidence. The SnapShots should be brief but should include the information that helps patients and physicians make important decisions about whether the device has benefits that outweigh the risks for patients.
Read More »December 12, 2024: Testimony of Dr. Siddiqui at FDA Vaccines and Related Biological Products Advisory Committee Meeting
December 12, 2024: NCHR Postdoctoral fellow Dr. Saman Siddiqui testified at the FDA Advisory Committee meeting about the need for better clinical trials of RSV vaccines for infants and toddlers because of serious risks in that age group.
Read More »